H Lundbeck completes two Nalmefene Phase III studies
ESENSE1 is a 24-week efficacy study, and SENSE, a 52-week safety study, were designed to investigate efficacy and safety of 20mg nalmefene taken ‘as needed’ versus placebo in
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
Doryx is a tetracycline-class antibacterial indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for